Document Detail


Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
MedLine Citation:
PMID:  19103995     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Statins reduce the risk of cardiovascular events in people with hypertension. This benefit could arise from a beneficial effect of statins on central aortic pressures and hemodynamics. The Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) study, an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy, investigated this hypothesis in a prospective placebo-controlled study of treated patients with hypertension. METHODS AND RESULTS: CAFE-LLA recruited 891 patients randomized to atorvastatin 10 mg/d or placebo from 5 centers in the United Kingdom and Ireland. Radial artery applanation tonometry and pulse-wave analysis were used to derive central aortic pressures and hemodynamic indices at repeated visits over 3.5 years of follow-up. Atorvastatin lowered low-density lipoprotein cholesterol by 32.4 mg/dL (95% confidence interval [CI], 28.6 to 36.3) and total cholesterol by 35.1 mg/dL (95% confidence interval, 30.9 to 39.4) relative to placebo. Time-averaged brachial blood pressure was similar in CAFE-LLA patients randomized to atorvastatin or placebo (change in brachial systolic blood pressure, -0.1 mm Hg [95% CI, -1.8 to 1.6], P=0.9; change in brachial pulse pressure, -0.02 mm Hg [95% CI, -1.6 to 1.6], P=0.9). Atorvastatin did not influence central aortic pressures (change in aortic systolic blood pressure, -0.5 mm Hg [95% CI, -2.3 to 1.2], P=0.5; change in aortic pulse pressure, -0.4 mm Hg [95% CI, -1.9 to 1.0], P=0.6) and had no influence on augmentation index (change in augmentation index, -0.4%; 95% CI, -1.7 to 0.8; P=0.5) or heart rate (change in heart rate, 0.25 bpm; 95% CI, -1.3 to 1.8; P=0.7) compared with placebo. The effect of statin or placebo therapy was not modified by the blood pressure-lowering treatment strategy in the factorial design. CONCLUSIONS: Statin therapy sufficient to significantly reduce cardiovascular events in treated hypertensive patients in ASCOT did not influence central aortic blood pressure or hemodynamics in a large representative cohort of ASCOT patients in CAFE-LLA.
Authors:
Bryan Williams; Peter S Lacy; J Kennedy Cruickshank; David Collier; Alun D Hughes; Alice Stanton; Simon Thom; Herbert Thurston;
Related Documents :
902045 - Minoxidil for severe hypertension after failure of other hypotensive drugs.
6499355 - Verapamil and propranolol in essential hypertension.
2402125 - Optimization of high-efficiency hemodialysis by detection and correction of fistula dys...
6777405 - Reproducibility of echocardiography in chronic congestive heart failure.
11549535 - Alveolar derecruitment at decremental positive end-expiratory pressure levels in acute ...
20133755 - General trend for pressurized superconducting hydrogen-dense materials.
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-12-22
Journal Detail:
Title:  Circulation     Volume:  119     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-06     Completed Date:  2009-02-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  53-61     Citation Subset:  AIM; IM    
Affiliation:
Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Building, Leicester Royal Infirmary, Leicester, UK. bw17@le.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aorta / physiology*
Blood Pressure / drug effects*
Brachial Artery / physiology
Cholesterol, LDL / blood
Female
Heptanoic Acids / administration & dosage*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Hyperlipidemias / drug therapy*,  physiopathology
Hypertension / drug therapy*,  physiopathology
Male
Middle Aged
Placebos
Pulsatile Flow / drug effects
Pyrroles / administration & dosage*
Radial Artery / physiology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Cholesterol, LDL; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Placebos; 0/Pyrroles; 110862-48-1/atorvastatin
Investigator
Investigator/Affiliation:
B Williams / ; P S Lacy / ; H Thurston / ; D O'Brien / ; P Swales / ; S Nanayakkara / ; A Stanley / ; K Edwards / ; W Gamble / ; V Garratt / ; J Harris / ; A Kirkham / ; Y Revell-Smith / ; L Bernhardt / ; S Thom / ; A Whitehouse / ; A D Hughes / ; J Macduff / ; S Leech / ; L Kinsley / ; O Trainor / ; Y Chim / ; A Jack / ; S Murphy / ; R Baruah / ; F Harrison / ; R Fernandez / ; A Strain / ; M Liboro / ; A Stanton / ; E O'Brien / ; E Dolan / ; D Farrell / ; O B Gallagher / ; S Lyons / ; G McCarthy / ; K Cruickshank / ; S Dean / ; J Dunkerley / ; M Banerjee / ; M Holland / ; M Hart / ; M Cullen / ; L Hardstaff / ; J Reynolds / ; J Collins / ; K Peters / ; M Luckson / ; D Collier / ; M Caulfield / ; C Waleczko / ; G Salahi-Ali / ; J Sheil / ; B Scott / ; S Wilson / ; C David / ; H Fok /
Comments/Corrections
Comment In:
Circulation. 2009 Jan 6;119(1):9-12   [PMID:  19103984 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Critical role of transcription factor cyclic AMP response element modulator in beta1-adrenoceptor-me...
Next Document:  Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis.